Log in to search using one of your social media accounts:

 

Reminder: Invitation to Roche ’s First Quarter Sales 2018 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - April 19, 2018 Category: Pharmaceuticals Source Type: news

Launch of Tecentriq in 2L+ NSCLC in Japan
(Source: Roche Investor Update)
Source: Roche Investor Update - April 18, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Hemlibra in haemophilia A without inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra ® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - April 17, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Roche announced today that new data on its approved and investigational medicines for neurological conditions will be presented during the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. (Source: Roche Investor Update)
Source: Roche Investor Update - April 16, 2018 Category: Pharmaceuticals Source Type: news

Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting
Roche today announced that it will present data from across its broad cancer immunotherapy development programme, including approved and investigational medicines, during the American Association for Cancer Research (AACR) Annual Meeting from 14 April to 18 April in Chicago, IL, United States. More than 42 abstracts have been accepted, including five “late breakers” and seven oral presentations. (Source: Roche Investor Update)
Source: Roche Investor Update - April 14, 2018 Category: Pharmaceuticals Source Type: news

Roche completes acquisition of Flatiron Health
Roche today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as well as in the curation and development of real-world evidence for cancer research. With its large network of community oncology practices and academic medical centers across the US, Flatiron Health has created a technology platform designed to learn from the experience of every patient. (Source: Roche Investor Update)
Source: Roche Investor Update - April 6, 2018 Category: Pharmaceuticals Source Type: news

Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra ® (emicizumab). (Source: Roche Investor Update)
Source: Roche Investor Update - March 28, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s First Quarter Sales 2018 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - March 27, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. (Source: Roche Investor Update)
Source: Roche Investor Update - March 26, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis ® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - March 22, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 20, 2018 Category: Pharmaceuticals Source Type: news

Save the date: Roche Analyst Event at ASCO 2018
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group ’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June 2018). (Source: Roche Investor Update)
Source: Roche Investor Update - March 14, 2018 Category: Pharmaceuticals Source Type: news

Roche Annual General Meeting 2018
Roche announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). (Source: Roche Investor Update)
Source: Roche Investor Update - March 13, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Enlarged Corporate Executive Committee
Roche today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the United States effective 2 April 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - March 8, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - February 27, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - February 27, 2018 Category: Pharmaceuticals Source Type: news

Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
Roche and Flatiron Health, Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. (Source: Roche Investor Update)
Source: Roche Investor Update - February 15, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review for Roche ’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of MabThera/Rituxan® (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - February 14, 2018 Category: Pharmaceuticals Source Type: news

Phase II data support potential for Roche ’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema
Roche today announced encouraging results from the Phase II BOULEVARD study. (Source: Roche Investor Update)
Source: Roche Investor Update - February 12, 2018 Category: Pharmaceuticals Source Type: news

Roche purchases shares in tender offer for Ignyta, Inc.
Roche and Ignyta, Inc. today announced that Roche ’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Ignyta, Inc. at a price of USD 27.00 per share in cash. (Source: Roche Investor Update)
Source: Roche Investor Update - February 8, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Virtual Pipeline Event
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Virtual Pipeline Event
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good results in 2017
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.” (Source: Roche Investor Update)
Source: Roche Investor Update - February 1, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s balovaptan in autism spectrum disorder
Roche announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational oral medicine balovaptan (previously known as RG7314), a vasopressin 1a (V1a) receptor antagonist for individuals with autism spectrum disorder (ASD). (Source: Roche Investor Update)
Source: Roche Investor Update - January 29, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - January 26, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Virtual Pipeline Event
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - January 26, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Full Year Results 2017 Presentation
Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - January 24, 2018 Category: Pharmaceuticals Source Type: news

TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC
(Source: Roche Investor Update)
Source: Roche Investor Update - January 19, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS ® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory ac tivity. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2018 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. at a price of US$ 27.00 per share. (Source: Roche Investor Update)
Source: Roche Investor Update - January 10, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Full Year Results 2017 Presentation
Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - January 8, 2018 Category: Pharmaceuticals Source Type: news

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment
Roche announced today that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients. (Source: Roche Investor Update)
Source: Roche Investor Update - January 8, 2018 Category: Pharmaceuticals Source Type: news

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
Roche announced today the launch of the cobas ® Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. By providing a small amount of a patient’s blood from a fingertip, this specially designed card simplifies blood collection and sample transportation. (Source: Roche Investor Update)
Source: Roche Investor Update - January 4, 2018 Category: Pharmaceuticals Source Type: news

Roche and Ignyta reach definitive merger agreement
Roche and Ignyta, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta ’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche. (Source: Roche Investor Update)
Source: Roche Investor Update - December 22, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa ® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors
Roche announced today that new data from the ongoing Hemlibra ® (emicizumab) clinical development programme were presented at the 59th American Society of Hematology (ASH) Annual Meeting. (Source: Roche Investor Update)
Source: Roche Investor Update - December 9, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A
Roche today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra ® (emicizumab) prophylaxis dosed once every four weeks in adults and adolescents (12 years of age or older) with haemophilia A with and without inhibitors to factor VIII. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2017 Category: Pharmaceuticals Source Type: news